Stem Cell Technologies and Applications will generate $15.8bn in 2019, According to a New Study on ASDReports

Tuesday 9 February 2016, Amsterdam

A new report, now available on ASDReports, forecasts that the worldwide stem cell technological and applications market will generate revenues of $15.8bn in 2019. That forecast and others appear in Stem Cell Technologies and Applications Market Report 2016-2026: Hype vs Reality for That Transformative Technology with Vast R&D Pipeline and Expanding Use of HSCT and Cord Blood Banking, published in November 2015.

Arshad Ahad, a senior pharmaceutical industry analyst said: “Stem cells have been seen for many years as an upcoming and potentially transformative technology. In 2015, the market has yet to realise its great potential, but stem cell technologies remain on the cusp of significant market expansion. Factors such as the increasing use of hematopoietic stem cell transplantation (HSCT), the launch of current pipeline therapies and the expanding use of cord blood banking services and stem cell-based assays will stimulate this market over the next ten years.

“However the industry has many barriers to overcome. Current reimbursement and regulatory systems will need to be updated to adapt to the unique challenges posed by these non-traditional therapies. In addition, companies will have to attract the attention of Big Pharma, which sometimes remains wary of this exciting but potentially risky field.”
This updated analysis gives revenue forecasting to 2026 for the overall stem cell technologies and applications market. It also shows revenue predictions from 2015 to 2026 for the following five submarkets:

• Cancer treatment (oncology)
• Cardiovascular therapy
• CNS uses
• Other therapies
• Non-therapeutic applications.

The report also provides revenue forecasts to 2026 for six stem cell therapies:

• MSC-100-IV (Mesoblast)
• Hearticellgram-AMI (Pharmicell)
• CardioRel (Reliance Life Sciences)
• Osteocel Plus (NuVasive)
• Trinity Evolution and Elite (Orthofix)
• CARTISTEM (MEDIPOST).

That investigation shows interviews with the Human Stem Cells Institute (HSCI), Apceth, MEDIPOST, Harvard Stem Cells Institute and the Stem Cell Program at Boston’s Children’s Hospital. It also discusses research and development, reviewing the most promising advances. The study also discusses leading companies, assessing their activities and potentials.